A cancer diagnosis — even one fully treated years ago — is one of the most complex underwriting scenarios in life insurance. Outcomes range from standard rates for certain early-stage skin cancers to outright decline for recent or metastatic disease. The type of cancer, stage, treatment, and time since last treatment are the four variables that drive everything.
What Underwriters Evaluate for Cancer History
Every cancer case is reviewed individually. These are the factors that determine whether you qualify, at what rating, and with which carrier:
Cancer Types: General Underwriting Outlook
Below is a general guide to how carriers approach the most common cancer types. Waiting periods are from date of last treatment with no recurrence. Individual cases vary significantly.
| Cancer Type | Typical Waiting Period | Best Achievable Rating | Notes |
|---|---|---|---|
| Basal Cell Skin Cancer | None required | Standard / Preferred | Generally disregarded by underwriters; treated as non-event |
| Squamous Cell Skin Cancer | 1–2 years (localized) | Standard | Localized and excised; more caution if lymph node involvement |
| Thyroid Cancer (Papillary) | 1–2 years post-treatment | Standard possible | Excellent prognosis; most carriers treat favorably after short waiting period |
| Prostate Cancer (Gleason 6, Stage 1–2) | 1–3 years post-treatment | Standard to Table 2 | Low-grade localized prostate treated favorably; higher Gleason scores require more time |
| Breast Cancer (Stage 1–2, ER+) | 2–5 years post-treatment | Table 2–4 at 2 years; standard possible at 5+ years | Hormone receptor status, lymph node involvement, and treatment type all factor in |
| Colon Cancer (Stage 1–2) | 2–5 years post-treatment | Table 2–4; standard possible at 5+ years | Stage 3 requires 5+ years; regular colonoscopy surveillance viewed positively |
| Melanoma (Clark Level I–II / Stage 1) | 1–3 years (thin lesion) | Standard to Table 2 | Breslow thickness and Clark level are key; deeper invasion requires longer waiting and higher ratings |
| Melanoma (Stage 2–3) | 5–10 years post-treatment | Table 4–8 at 5 years; standard possible at 10+ years | Lymph node involvement significantly increases scrutiny |
| Cervical Cancer (Stage 1) | 2–3 years post-treatment | Standard to Table 2 | CIS (Stage 0) often ignored; Stage 1 treated favorably after waiting period |
| Bladder Cancer (Low-Grade, Non-Invasive) | 2–3 years post-treatment | Table 2–4 | High recurrence rate noted by underwriters; surveillance history matters |
| Hodgkin’s Lymphoma (Stage 1–2) | 5 years post-treatment | Table 2–4 at 5 years; standard possible at 10+ years | Good long-term prognosis; late treatment effects (cardiac, secondary malignancy) monitored |
| Lung Cancer | 5+ years (Stage 1 only) | Table 4–8 minimum; decline at most carriers | Extremely restrictive; Stage 2+ is decline at virtually all carriers regardless of time elapsed |
| Pancreatic Cancer | Postponement / Decline | Decline at virtually all standard carriers | Even with surgery and remission, extremely few carriers will consider; guaranteed issue may be only option |
Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.
Carrier Guidelines: Cancer Underwriting Comparison
Carriers vary significantly in their willingness to cover cancer survivors and in how many years of remission they require. Below are current general approaches across major carriers we represent.
| Carrier | Minimum Remission (Breast/Colon) | Skin Cancer Approach | Notes |
|---|---|---|---|
| Protective Life | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after 1–2 years | Competitive for early-stage breast and colon; strong thyroid and prostate outcomes |
| Banner Life / Legal & General | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell reviewed individually | Competitive term pricing for cancer survivors with clean remission records |
| Prudential | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after treatment | Medical director review available for complex cases; competitive for melanoma survivors |
| Pacific Life | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard post-treatment | Strong for prostate cancer survivors; favorable thyroid cancer treatment |
| Transamerica | 2–3 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell reviewed case-by-case | More conservative on breast cancer; competitive on pricing at table ratings for qualifying cases |
| North American Company | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after excision | Solid option for straightforward cancer survivor cases; less competitive on complex histories |
| Lincoln Financial | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after treatment | Requires complete oncology records; competitive for well-documented remission cases |
| Mutual of Omaha | 2–3 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell reviewed individually | Strong simplified issue and final expense options for cases that don’t qualify fully underwritten |
Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.
Situations That Typically Result in Decline
The following scenarios result in postponement or decline at most or all fully underwritten carriers. Alternative products such as graded benefit or guaranteed issue may be available.
What You Can Do to Improve Your Outcome
Cancer History? Let’s Find the Right Carrier.
Cancer underwriting requires matching your specific diagnosis, stage, treatment, and time in remission to the carrier whose guidelines are most favorable for your profile. We know which carriers are most competitive for which cancer types — and we’ll tell you before you apply anywhere.
Browse All High-Risk Conditions
Atrial Fibrillation (AFib) | Heart Attack / Heart Disease | High Blood Pressure | Stroke / TIA | Diabetes | Obesity / High BMI | Thyroid Disease | COPD / Emphysema | Sleep Apnea | Lupus | Multiple Sclerosis | Rheumatoid Arthritis | Kidney Disease (CKD) | Hepatitis B & C | Crohn’s Disease | Ulcerative Colitis | Anxiety / Depression | Bipolar Disorder | Epilepsy | PTSD | HIV / AIDS | DUI / DWI | Drug Use / Abuse | Marijuana Use | Aviation / Pilots | Drag Racing
Understanding Your Rating: Life Insurance Risk Classifications | Table Ratings Explained (B–J) | Flat Extra Ratings
Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.
Frequently Asked Questions
How long after cancer treatment can I get life insurance?
Waiting periods depend heavily on cancer type, stage, and grade. Early-stage (Stage I) cancers treated with clean surgical margins often qualify for traditional coverage after a 1 to 2 year remission period. Stage II typically requires 2 to 5 years cancer-free. Stage III generally needs 5 to 10 years of stable remission. Stage IV historically required 10 years or more, though some carriers now consider certain well-controlled Stage IV cancers at 5 years. Basal cell and most squamous cell skin cancers, plus in-situ cancers, often have no waiting period at all.
Which cancer types are easiest to get life insurance with?
Breast cancer caught early (Stage 0 or Stage I), prostate cancer with low Gleason scores, thyroid cancer, early-stage melanoma, and most non-melanoma skin cancers are generally the most insurable. These often qualify for Standard or Table-rated offers within 1 to 3 years of treatment completion. Harder-to-insure cancers include pancreatic, liver, lung (especially small cell), ovarian, and metastatic cancers of any origin — these typically require longer remission periods and result in higher table ratings or declines.
Can I get Preferred rates after surviving cancer?
Preferred Plus rates are almost never available to cancer survivors at any carrier. Preferred is possible for very low-risk cases — typically Stage 0 or I cancers with 10 or more years of clean remission and no recurrence. Most cancer survivors qualify at Standard through Table 4, with the specific rating depending on stage, time since treatment, cancer type, and age at diagnosis. Prudential is well-known for competitive post-cancer underwriting; John Hancock, Protective, and Mutual of Omaha also have specialized programs for survivors.
What medical records will underwriters request for a cancer history?
Underwriters will request pathology reports (confirming cancer type, stage, and grade), surgical records, oncology treatment summaries (chemotherapy, radiation, immunotherapy, or targeted therapy received), and all follow-up imaging and lab work. Key data points include: staging at diagnosis, surgical margins, lymph node involvement, treatment response, current surveillance schedule, tumor markers if applicable, and date of last clean scan. Having your oncologist’s most recent note and imaging reports ready speeds underwriting substantially.
Does family history of cancer affect my underwriting if I’m healthy?
It can, depending on the cancer and how close the relative is. Strong family history of early-onset cancers (breast, ovarian, colon, pancreatic) in first-degree relatives may trigger additional underwriting questions about genetic testing (BRCA1/2, Lynch syndrome) and screening compliance. A positive BRCA result without personal cancer history is handled differently by different carriers — some apply mild ratings, others don’t rate if you’re actively in a high-risk screening program. Distant or late-onset family cancer typically has minimal impact on rate class.